Aoun M
Laboratoire de Microbiologie et Département des Maladies Infectieuses, Institut Jules Bordet, ULB, Bruxelles.
Rev Med Brux. 2004 Jun;25(3):166-71.
Voriconazole is a fluoropyrimidine derivative of fluconazole with an extended spectrum of activity, non-linear pharmacokinetic characteristics, available intravenously and orally with an excellent bioavailability, and a good penetration into tissues including the brain. It is metabolized in the liver by the cytochrome P450 and less than 1% is eliminated in the urine. Voriconazole has been studied extensively in numerous randomized clinical trials of invasive fungal infections and became the therapy of choice of invasive aspergillosis, fusariosis and scedosporiosis. Voriconazole is an alternative for invasive candidiasis refractory or resistant to fluconazole. Voriconazole has a good tolerability and acceptable safety profile and has added a new weapon to our therapeutic armamentarium against fungi.
伏立康唑是氟康唑的氟嘧啶衍生物,抗菌谱更广,具有非线性药代动力学特征,可静脉给药和口服,生物利用度极佳,能很好地渗透到包括脑在内的组织中。它在肝脏中通过细胞色素P450代谢,不到1%经尿液排出。伏立康唑在众多侵袭性真菌感染的随机临床试验中得到广泛研究,成为侵袭性曲霉病、镰刀菌病和赛多孢子菌病的首选治疗药物。伏立康唑是对氟康唑难治或耐药的侵袭性念珠菌病的替代药物。伏立康唑耐受性良好,安全性可接受,为我们对抗真菌的治疗手段增添了新武器。